Sivapatham Sundaresan

SRM Institute of Science and Technology

Dr. S. Sundaresan has been working in the field of cancer chemoprevention, cancer immunotherapy, and tumor marker detection. Translational research (TR) has been described as translating research into medical practice and translating science into better healthcare. Translational research on tumor biomarkers has successfully promoted the development of tumor treatment and has brought new hope for cancer patients. It is important to direct cancer research on diagnosis and treatment toward applying fundamental research findings to the clinic as soon as possible, and applying novel tumor molecular markers to early diagnosis, targeted therapy, and individualized treatment. Focused medical treatment should be given through the analysis of new tumor biomarkers and appropriate treatments. Dr. S. Sundaresan has been working with oral cancer and cancer biomarkers. There are newer molecular markers that are of clinical significance and they need to be studied in various populations. The administration of indoles and triterpenes for preventive and curative effects was studied in laboratory animals. Dr. S. Sundaresan’s research study also demonstrates interferon beta synergistically works with chemotherapeutic drug cisplatin for liver, breast, and cervix cancer cells.

2books edited

2chapters authored

Latest work with IntechOpen by Sivapatham Sundaresan

Translational research in oncology benefits from an abundance of knowledge resulting from genome-scale studies concerning the molecular pathways involved in tumorigenesis. Translational oncology represents a bridge between basic research and clinical practice in cancer medicine. The vast majority of cancer cases are due to environmental risk factors. Many of these environmental factors are controllable lifestyle choices. Experimental cancer treatments are studied in clinical trials to compare the proposed treatment to the best existing treatment through translational research. The key features of the book include: 1) New screening for the development of radioprotectors: radioprotection and anti-cancer effect of β-Glucan (Enterococcus faecalis) 2) Translational perspective on hepatocellular carcinoma 3) Brachytherapy for endometrial cancer 4) Discovery of small molecule inhibitors for histone methyltransferases in cancer

Go to the book